Valneva Wins "Fastest Growing Listed
Company" Tech 50 Award for France by
Deloitte
Valneva SE ("Valneva" or "the Company"), a fully integrated,
commercial stage biotech company focused on developing innovative
life-saving vaccines, today announced that it has won the "Fastest
Growing Listed Company" Award for France in the 2016 Deloitte In
Extenso Technology Fast 50(TM) ranking. Valneva also ranked 43 out
of 500 companies in Deloitte's 2016 Technology Fast 500(TM) EMEA.
The Technology Fast 50 and Fast 500 initiatives
reward the fastest growing technology, media, telecommunications,
life sciences and energy tech companies - both public and private -
in France and the EMEA region. Award winners are selected for
demonstrating innovation, leadership, and rapid revenue growth over
their last four years of operations.
Laurent Halfon, Deloitte Partner and
country manager of the Technology Fast 50 program in
France, commented, "The Technology Fast 50 ranking
promotes companies like Valneva which reflect the incredible drive
for innovation and added value creation of French entrepreneurs.
Already in its 16th edition, the Technology Fast 50 France ranking
has become a true reference for French and international investors.
We are proud to see Valneva among the winners for 2016."
Thomas Lingelbach, President and CEO,
and Franck Grimaud, Deputy CEO of Valneva, added, "This
award underpins the underlying rationale of Valneva's strategy
focused on growing revenues through a combination of organic and
strategic growth while continuing to invest in promising Research
& Development programs and activities."
Following a strong business performance in the
first nine months of 2016, Valneva recently increased its financial
guidance and expects revenues between €95 and €100 million in 2016
and an EBITDA profit of €1-5 million. Valneva will continue to
build commercial and R&D value in the coming years and expects
to grow its revenues to approximately €250 million by 2020.
About Deloitte
Deloitte refers to Deloitte Touche Tohmatsu
Limited, a UK private company limited by guarantee, and its network
of member firms, each of which is a legally separate and
independent entity. Please see www.deloitte.com/about for a
detailed description of the legal structure of Deloitte Touche
Tohmatsu Limited and its member firms. In France, Deloitte SAS is
the member firm of Deloitte Touche Tohmatsu Limited, and
professional services are provided by its subsidiaries and
affiliates.
Deloitte provides audit, tax, consulting, and
financial advisory services to public and private clients spanning
multiple industries. With a globally connected network of member
firms in more than 150 countries, Deloitte brings world-class
capabilities and high-quality service to clients, delivering the
insights they need to address their most complex business
challenges. Deloitte's approximately 244,000 professionals are
committed to becoming the standard of excellence.
About Deloitte Technology Fast
500 TM EMEA
The Deloitte Technology Fast 500EMEA programme
is the region's most objective EMEA region industry-ranking to
focus on the technology field, recognising tewchnology companies
that have achieved the fastest rates of revenue growth in Europe,
the Middle East, and Africa.
Combining technology innovation,
entrepreneurship and rapid growth, Fast 500 companies span a
variety of industry sectors, and are leaders in hardware, software,
communications, media, life sciences and clean technology.
The programme is supported by the Deloitte
Technology Fast 50 initiatives, which rank high growth technology
companies by location or specifically defined geographic area and
is run by the Deloitte Touche Tohmatsu Limited's Technology. More
information on the programme and winners is available on
www.deloitte.com/fast500emea
About Valneva SE
Valneva is a fully integrated vaccine company
that specializes in the development, manufacture and
commercialization of innovative vaccines with a mission to protect
people from infectious diseases through preventative medicine.
The Company seeks financial returns through
focused R&D investments in promising product candidates and
growing financial contributions from commercial products, striving
towards financial self-sustainability.
Valneva's portfolio includes two commercial
vaccines for travelers: IXIARO®/JESPECT® indicated for the
prevention of Japanese encephalitis and DUKORAL® indicated for the
prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has proprietary vaccines in
development including candidates against Clostridium difficile and
Lyme Borreliosis. A variety of partnerships with leading
pharmaceutical companies complement the Company's value proposition
and include vaccines being developed using Valneva's innovative and
validated technology platforms (EB66® vaccine production cell line,
IC31® adjuvant).
Valneva is listed on Euronext-Paris and the
Vienna stock exchange and has operations in France, Austria, Great
Britain, Sweden, Canada and the US with over 400 employees. More
information is available at www.valneva.com.
Contacts
Laetitia
Bachelot-Fontaine Teresa
Pinzolits
Head of Investor
Relations Corporate
Communications
& Corporate
Communications
T +43-1-206 20-1116
T
+02-28-07-14-19
M +43-676-84 55 67 357
M +33 (0)6 4516
7099 communications@valneva.com
investors@valneva.com
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/f6a3c8ea-e895-49de-ba4a-2c1f70027311